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ABSTRACT
Cell surface mannose 6-phosphate/insulin-like
growth factor II receptors (M6P/IGF2R) bind and
target exogenous insulin-like growth factor II (IGF2)
to the prelysosomes where it is degraded. Loss of
heterozygosity (LOH) for M6P/IGF2R is found in
cancers, with mutational inactivation of the remain-
ing allele. We exploited the normal allele-specific
differential methylation of the M6P/IGF2R intron
2 CpG island to rapidly evaluate potential LOH in
ovarian cancers, since every normal individual is
informative. To this end, we developed a method for
bisulfite modification of genomic DNA in 96-well
format that allows for rapid methylation profiling.
We identified ovarian cancers with M6P/IGF2R LOH,
but unexpectedly also found frequent abnormal
acquisition of methylation on the paternally inherited
allele at intron 2. These results demonstrate the
utility of our high-throughput method of bisulfite
modification for analysis of large sample numbers.
They further show that the methylation status of the
intron 2 CpG island may be a useful indicator of
LOH and biomarker of disease.
INTRODUCTION
The mannose 6-phosphate/insulin-like growth factor II
receptor (M6P/IGF2R) encodes a multifunctional protein
that is involved in lysosomal sorting, latent TGFb activation
and binding the potent mitogen, insulin-like growth factor II
(IGF2). IGF2 binding to the M6P/IGF2R causes IGF2 to be
internalized and degraded in the prelysosomal compartment
(1). Loss of M6P/IGF2R function leads to increased extra-
cellular IGF2 and decreased activated TGFb. These mole-
cular effects increase cell proliferation, decrease apoptosis,
and enhance tumor invasion and metastasis, suggesting that
IGF2R functions as a tumor suppressor (2). This is supported
by observations indicating that loss ofheterozygosity(LOH) is
frequent in breast, lung and liver cancers, with mutational
inactivation of the remaining allele (3–6).
Mouse M6p/Igf2r is subject to genomic imprinting (7,8),
a form of epigenetic regulation that results in parent of
origin dependent monoallelic expression. M6p/Igf2r has two
differentially methylated CpG islands. The ﬁrst (region 1)
encompasses the promoter and is methylated on the repressed
paternally inherited allele, whereas the intron 2 CpG island
(region 2) is methylated on the expressed maternally inherited
allele (9). Region 2 methylation is established during oogen-
esis and constitutes the inherited imprint mark, whereas
region 1 is methylated postfertilization (9). An M6p/Igf2r
antisense transcript is produced from within region 2 in
mice on the paternally inherited chromosome and this is
required for imprinted expression of M6p/Igf2r. For all tissues
thus far examined, humans do not exhibit imprinted expres-
sion of M6P/IGF2R, with biallelic expression evident
throughout the primate lineage (10). Furthermore, an antisense
transcript in humans has not been reported. However, similar
to mice, humans do exhibit maternal methylation of ortho-
logous region 2 (11). It is unclear whether the differ-
ential methylation of region 2 in humans is functionally
relevant, or a vestige of the evolutionary loss of imprinted
expression.
Previous microarray analysis of 58 advanced stage serous
epithelial ovarian cancers (12) indicated that the average
transcription of the M6P/IGF2R is decreased in most cancers
compared with that observed for normal ovarian surface epi-
thelium (N ¼ 3; Affymetrix U133A GeneChips; 858.7 versus
2064.2, respectively, P ¼ 0.04, t-test, Welch-corrected). This
difference in expression might be due to LOH. We were there-
fore interested in generating an assay to rapidly screen for
potential M6P/IGF2R LOH that exploits the differentially
methylatedstatusofregion2.Suchatechniquewouldimprove
upon genetic polymorphism-based analysis in that every
sample is ‘heterozygous’ by virtue of the allele-speciﬁc
differential methylation of this region.
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doi:10.1093/nar/gkj468Sodium bisulﬁte converts unmethylated cytosines to uracil,
while methylated cytosines are unaffected (13). Bisulﬁte
treatment of DNA is presently a widely used tool in conduct-
ing DNA methylation analysis, and most studies employ
either commercially available kits or variations of the method
pioneeredbyFrommeretal.(13),andmorerecentlyoptimized
by Grunau et al. (14). The hands-on manipulations required
using these methods limit the number of samples that can
be simultaneously treated (in our hands,  20) and this poten-
tially inﬂuences the consistency between preparations. In
the present study, we modiﬁed the smaller scale bisulﬁte
treatment protocol, (hereafter referred to as SSBM, for single
sample bisulﬁte modiﬁcation) to develop an assay for high-
throughput bisulﬁte modiﬁcation (HTBM) taking advantage
of a 96-well format. We validated this assay by analyzing the
differentially methylated region (DMR) associated with the
imprinted maternally expressed gene 3 (MEG3) (15). We then
used HTBM to prepare samples for analysis of M6P/IGF2R
region 2 in ovarian and breast cancers. Surprisingly, we found
a very high frequency of hypermethylation in both types of
cancer. We conﬁrmed suspected LOH based on this methyla-
tion proﬁle in ovarian cancers using genetic polymorphism
analysis.
MATERIALS AND METHODS
Tissue samples and nucleic acid purification
Normal human genomic DNA used for validation and com-
parison of the HTBM and SSBM methods was purchased from
Promega (Madison, WI). CpGenome Universal Methylated
DNA (Chemicon International; Temecula, CA) was used as
a control. Genomic DNA was prepared using PUREGENE
Reagents (Gentra Systems; Minneapolis, MN). All tissues
were obtained with patient consent. The Duke University
Medical Center Institutional Review Board approved this
study.
Bisulfite modification of genomic DNA
High-throughput bisulfite modification. Based on experi-
mental parameters published by Grunau et al. (14), we adjus-
ted the reaction components proportionately to accommodate
a 96-well format. Incubation steps were performed in a
heated lid thermocycler. DNA (3 ng to 2 mgi na1 0ml volume)
was denatured with 1.1 ml freshly prepared 3 M NaOH
(VWR; Westchester, PA) for 20 min at 42 C, then mixed
with 120 ml sodium bisulﬁte solution (saturated sodium
bisulﬁte, 10 mM hydroquinone, pH 5.0). The bisulﬁte solution
was prepared as follows: 10.8 g sodium bisulﬁte (Sigma-
Aldrich; St Louis, MO) was brought to 16 ml ﬁnal volume
in water and inverted gently to mix. We added 2.6 ml freshly
prepared 3 M NaOH followed by 1.0 ml hydroquinone
solution [prepared by dissolving 0.22 g hydroquinone
(Sigma-Aldrich) in 10 ml water]. Undissolved bisulﬁte
will remain in the solution since it is saturated; we therefore
ﬁltered the solution prior to use with a 0.45m ﬁlter. The
samples in bisulﬁte solution were incubated for 4 h
at 55 C.
An aliquot of 100 ml nuclease-free water was then added
to each well followed by transfer to a Montage PCR96 96-well
ﬁltration plate (Millipore, Billerica, MA). The size exclusion
ﬁltration matrix in these plates prevents ﬂow-through of
fragments >200 bp. All remaining steps of the protocol
were performed in the Montage PCR96 ﬁltration plate using a
vacuum manifold (Millipore MultiScreen Vacuum Manifold)
and an in-house vacuum source. The solution was drawn
through the ﬁltration matrix by vacuum (20–25 inches Hg)
until the wells were visibly empty of solution, typically requir-
ing about 5 min. The DNA was desalted with 175 ml nuclease-
free H2O three times followed by desulfonation with 175 mlo f
0.1 M NaOH (with immediate vacuum ﬁltration) and a ﬁnal
wash step with 175 mlH 2O. The DNA was recovered in 50 ml
of 10 mM Tris/HCl (pH 8.0) by using a plate shaker to release
the DNA from the ﬁltrationmatrix for 10 min (Vortex Genie 2,
setting  5) followed by transfer to individual tubes and
storage at  20 C.
Single sample bisulfite modification (SSBM). SSBM followed
the method described previously (14,15) except that the
DNA was resuspended in 50 ml 10 mM Tris/HCl, pH 8.0
and stored at  20 C.
Methylation-specific PCR (MS-PCR)
MS-PCR and bisulﬁte sequencing for the DLK1/MEG3
DMR were performed as described previously (15) without
multiplexing the reactions.
The primers for MS-PCR of M6P/IGF2R region 2 were MF
50-CGG TTT TTT GCG GTT TTT CGT C-30;M R5 0-AAC
CCA ACC GCA CGA CCA C-30;U F5 0-GGT TTT TTG TGG
TTT TTT GTT GGT GTT G-30; and UR 50-AAT AAC CCA
ACC ACA CAA CCA CAC TAA CA-30. The primers for
M6P/IGF2R region 1 were MF 50-GTT GTC GTC GAG
TTT AGT CGA GTC-30;M R5 0-GCG CGA CTA CTA AAA
CCG-30;U F5 0-GTT GTT GTT GAG TTT AGT TGA GTT
GTG-30; and UR 50-CTA ACA ACA CAC AAC TAC TAA
AAA CCA C-30. All primers were obtained from Sigma-
Genosys (The Woodlands, TX).
Bisulﬁte-treated DNA (30–60 ng) was ampliﬁed in a 25 ml
reaction volume containing 1· reaction buffer, 3 mM MgCl2,
0.2 mM each dNTP, 2.5 U Platinum Taq DNA Polymerase
(Invitrogen; Carlsbad, CA), and 0.4 mM each forward and
reverse M or U primer. Cycling conditions for M6P/IGF2R
region 2 MS-PCR were 3min at 94 C followed by 35 cycles of
30 s at 94 C, 30 s at 69 C and 30 s at 72 C and ﬁnal extension
of 5 min at 72 C. The cycling conditions for M6P/IGF2R
region 1 were 3 min at 94 C followed by 40 cycles of 30 s
at94 C,45sat62 Cand45sat72 Candﬁnal5minextension
at 72 C.
Bisulfite sequencing
Bisulﬁte-treated genomic DNA was PCR ampliﬁed (3 min
at 94 C followed by 35 cycles of 30 s at 94 C, 30 s at
55 C and 30 s at 72 C with a 5 min ﬁnal extension at
72 C) with primers speciﬁc for bisulﬁte converted MEG3
DMR as described previously (15) in a 25 ml reaction volume
containing 3 ml of each titration of the bisulﬁte-treated DNA
template, 3 mM MgCl2, 0.2 mM dNTPs and 0.4 mM each
primer. The 235 bp PCR products were resolved on a 2.5%
agarose gel, puriﬁed using Sigma GenElute spin columns
(Sigma; St Louis, MO) and cycle sequenced (15) (Thermo
556 Nucleic Acids Research, 2006, Vol. 34, No. 2Sequenase Radiolabeled Terminator Cycle Sequencing kit;
Amersham Biosciences, Piscataway, NJ). Thermocycler
conditions were 35 cycles of 30 s at 95 C, 30 s at 55 C
and 60 s at 72 C. The sequencing products were resolved
on a 5% denaturing polyacrylamide sequencing gel followed
by exposure at  80 C to radiographic ﬁlm with an intensify-
ing screen.
Analysis of cloned amplicons from HTBM-treated
genomic DNA
PCR amplicons were generated using 40 ng bisulﬁte modiﬁed
DNA with primers speciﬁc for M6P/IGF2R region 2: F1,
50-TGA ATT TGG AGT TTG GGG TTT GTA GTG TTG
GGA GGT-30 and R1, 50-CTA ACA AAT TCA AAA ACC
AAA CCC CCA AC-30. Because of the very limited DNA
from normal OSEs 1–5, 1 ml was used as template in a 10 ml
reaction volume. All other PCRs were 25 ml total volume. PCR
conditions were 94 C for 3 min followed by 40 cycles of
94 C for 30 s, 66 C for 30 s and 72 C for 30 s with a ﬁnal
5 min extension at 72 C. The amplicons were resolved on
2% agarose gels, puriﬁed using the Qiagen MinElute PCR
Cleanup kit (Valencia, CA), ligated into pGEMT-Easy vectors
(Promega; Madison, WI) and plasmids were transformed
into competent JM109 Escherichia coli (Promega; Madison,
WI) followed by plating to LB agar with 100 mg/ml
ampicillin (TEKNOVA; Hollister, CA). Whole cell PCR
was used to amplify plasmids from individual colonies
using SP6 and T7 primers (94 C for 5 min, then 35 cycles
of 94 C for 30 s, 55 C for 30 s, 72 C for 30 s, ﬁnal 5 min
extension at 72 C). The amplicons were resolved on agarose
gels, puriﬁed, and sequenced using the F1 primer.
Laser capture microdissection and LOH analysis
Seven micron sections were cut from frozen Tissue-Tek 
cryomold blocks (Sakura; Torrance, CA) and brieﬂy stained
with hematoxylin and eosin prior to capture of normal and
malignant cells. Slides were dehydrated using a series of
graded ethanol washes. Laser capture was performed using
the Veritas Microdissection System (Arcturus Bioscience,
Inc.; Mountain View, CA). DNA from normal and malignant
cells was prepared using PUREGENE reagents (Gentra
Systems; Minneapolis, MN) followed by genotyping with pri-
mers that ﬂank polymorphic sites located in the M6P/IGF2R
intron 2 DMR (rs8191722) (forward: 50-CTG GCA TGT TGG
GGA CAG GT-30; reverse: 50-GAA GCG GGA AGG GAG
TGA CC-30) and/or an A/G SNP located at position 2286 of
the M6P/IGF2R transcript (NM_000876) in exon 16 (forward:
50-GTG ACT CCT CAC GTC GCT CAC G-30; reverse:
50-CAC AGG CAT GAG TAT CCT CAG G-30). The PCR
amplicons were puriﬁed using Sigma GenElute spin columns
(Sigma-Aldrich; Saint Louis, MO) followed by nucleotide
sequencing using the primer 50-CTG CCT GGC CCT TGT
CTG G-30 for intron 2 and primer 50-GGG TCT GAG TAA
TGC GAA GC-30 for exon 16. The sequencing reactions were
resolved on 5% denaturing polyacrylamide gels, dried and
analyzed using Phosphorimager analysis (Storm 840 Scanner
and ImageQuant Software; GE Healthcare Piscataway, NJ).
An allelic imbalance in the malignant cells >4:1 was
considered positive for LOH.
RESULTS
Comparison of bisulfite modification methods
and validation of HTBM
We treated increasing amounts of human genomic DNA using
both methods and assessed the results using MS-PCR and
bisulﬁte sequencing of the MEG3 DMR on human chromo-
some 14q32.2 (15) (Figure 1). Universally methylated (in vitro
methylated; ivM) and untreated (UT) human genomic DNA
were included as controls. As shown in Figure 1A, the primers
speciﬁc for methylated (M) and unmethylated (U) DNA pro-
duce 160 and 120 bp amplicons, respectively. An aliquot of
2 ml of each DNA sample was used as template for MS-PCR
from the 50 ml used to recover the modiﬁed DNA. MS-PCR
amplicons were detectable for both the U and M primers using
both methods, even from 3 ng of treated DNA.
Using 0.5–10 ml of the 300 ng input HTBM sample as
template, we also determined the amount of modiﬁed DNA
required to produce optimal yields of MEG3 MS-PCR amp-
licons (Figure 1B). The results indicate that 0.5 ml is sufﬁcient,
although increasing the template produced higher yields and
did not appear to compromise speciﬁcity.
Bisulﬁte sequencing is regarded as a comprehensive
method for determining methylation status since it provides
information for each CpG dinucleotide as well as a visual
representation of the conversion efﬁciency for non-CpG
(unmethylated) cytosines. In order to assess conversion efﬁ-
ciency of the HTBM method, we performed bisulﬁte sequen-
cing of the MEG3 DMR (15) using DNA treated in increasing
amounts by HTBM (Figure 1C). The control in vitro methyl-
ated template showed complete methylation of each CpG.
Because this region is differentially methylated, we observed
equivalent amounts of unmethylated and methylated cytosines
at each CpG position in the sequence for the normal DNA
(arrows). Importantly, each non-CpG cytosine was fully
converted by HTBM (arrowheads). Surprisingly, we obtained
good quality sequence from the amplicon generated from the
3 ng sample, indicating that degradation was negligible
during the HTBM procedure.
Analysis of M6P/IGF2R methylation status
in normal and malignant tissues
We used HTBM to prepare genomic DNA from cancers and
normal lymphocytes to determine the utility of using the dif-
ferential methylation of M6P/IGF2R region 2 as an indicator
for potential LOH. The M6P/IGF2R consists of 48 exons
spanning  137.5 kb (Figure 2) with three associated CpG
islands: one encompassing the promoter that is normally
unmethylated (region 1), one in intron 2 that exhibits differ-
ential methylation (region 2) and one in intron 44 whose
methylation status is unknown.
We treated 300 ng genomic DNA from each specimen,
recovered the DNA in 50 ml and used 2 ml of this as template
in 25 ml MS-PCRs. Most normal lymphocyte samples gave a
roughly equal distribution of unmethylated and methylated
amplicons by MS-PCR (Figure 3A). One showed slightly
more methylated amplicons for region 2 (NL7), indicating
that there may be inter-individual variability in the degree of
methylation present in this region. This was also noted for a
normal ovarian surface epithelium sample that had undergone
Nucleic Acids Research, 2006, Vol. 34, No. 2 557Figure 1. Comparison of HTBM and SSBM and validation of HTBM. (A) Increasing amounts of human genomic DNA were modified using HTBM and SSBM
followed by MS-PCR of the MEG3 DMR on human chromosome 14q. An aliquot of 500 ng CpGenome Universal Methylated DNA (ivM) was also modified
using each method and used as a control. Both methylated (M, 160 bp) and unmethylated (U, 120 bp) DNA products were detected using bisulfite-treated samples.
L, 50 bp ladder; ivM, Universal Methylated DNA; UT, untreated genomic DNA; H20, water control. (B) MS-PCR of the MEG3 DMR using increasing amounts of
the 300 ng input genomic DNA treated using the HTBM protocol. (C) Validation of conversion efficiency of HTBM by bisulfite sequencing of the MEG3 DMR.
The indicated amounts of normal human genomic DNA and 500 ng of the Universal Methylated DNA (ivm) were prepared using HTBM, amplified using primers
specific for the MEG3 DMR that do not anneal to regions containing CpG dinucleotides, and manually sequenced. Cytosines in 50-CpG-30 context in the original
unconverted sequence are indicated by black arrows, while non-CpG cytosines are indicated by the open arrowheads.
Figure2.M6P/IGF2Rgenomicstructure.TheM6P/IGF2Rlocusconsistsof48exons(verticallines)andisassociatedwiththreeCpGislands(ovals).Region1isthe
promoter CpG island, whileregion 2 is a DMRlocatedwithin intron2. Region2 is characterizedby maternal(MAT) allele-specific methylation, while the paternal
allele (PAT) is unmethylated. The direction of transcription is indicated. The relative location of primers used for sequencing and for methylation-specific PCR is
shown below. Numbered circles represent CpG dinucleotides present within the region (not to scale) and analyzed in the present study.
558 Nucleic Acids Research, 2006, Vol. 34, No. 2several passages in culture (OSEc). MS-PCR analysis of DNA
from over 60 serous epithelial ovarian tumors showed the
majority exhibit an increased yield of methylated amplicons
for region 2, with some producing only methylated amplicons
(Figure 3B).
To determine whether the apparently increased methylation
at region 2 of M6P/IGF2R is associated with methylation
spreading from an aberrantly methylated promoter CpG island
(region 1), we analyzed 12 tumors by MS-PCR for regions
1 and 2 along with several normal lymphocyte samples
Figure 3. Methylation-specific PCR of M6P/IGF2R region 2. (A) MS-PCR of region 2 using HTBM-treated peripheral blood lymphocytes (NL) and a primary
cultureofnormalovariansurfaceepithelium(OSEc).L,50bpladder;U,primersusedspecificforunmethylatedDNAwhichproducea139bpamplicon;M,primers
used specific for methylated DNA which produce a 137 bp amplicon; nt, H2O control. (B) HTBM DNA from primary serous epithelial ovarian cancers was treated
usingHTBMandanalyzedbyMS-PCRasdescribedin(A).(C)HTBMDNAfromprimaryserousepithelialovariancancerswassubjectedtoMS-PCRwithprimers
for the M6P/IGF2R promoter CpG island (region 1, ‘1’) and to region 2 (‘2’). (D) HTBM DNA from matched lymphocytes (N) and ovarian malignancies
(M, mucinous; S, serous) was subjected to MS-PCR for M6P/IGF2R region 2 as described above. (E) M6P/IGF2R MS-PCR of region 2 using HTBM DNA from
primary breast cancers (B) and normal lymphocytes (NL).
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lymphocytes and in the OSEc sample, both methylated and
unmethylated amplicons were obtained for region 2 while
only unmethylated amplicons were obtained for region 1.
For 11 of the tumors with increased region 2 methylation,
region 1 was completely unmethylated. In one case (number
60), methylation was indeed detected at region 1, suggesting
the possibility of a regional methylation defect in this indi-
vidual. Nevertheless, these results indicate that methylation
spreading from the promoter is not associated with the fre-
quent increase in methylated amplicons detected for region 2.
To establish whether the methylation changes observed by
MS-PCR were speciﬁc to the malignancies, we analyzed
HTBM tumor and matched lymphocyte DNA by MS-PCR
(Figure 3D). Complete methylation was observed in an ovar-
ian teratoma for region 2, while the matched lymphocytes
yielded both unmethylated and methylated amplicons by
MS-PCR. The absence of the unmethylated (paternally
derived) amplicon in the teratoma is indicative of the maternal
derivation of the genetic material in these types of neoplasms.
For mucinous ovarian cancers M1 and M2, the methylation
proﬁles did not differ substantially between tumor and
lymphocytes, while for M3, a stronger signal was present in
both tissues for methylated region 2. Matched lymphocytes
from four of eight serous ovarian tumors had relatively normal
differential methylation (S1–S4), while lymphocytes from
S5–S8 appeared to be hypermethylated. Every one of these
serous cancers exhibited increased methylated amplicons. We
cannot rule out at this point that the increased methylation
detected in lymphocytes is not from circulating tumor DNA.
This seems unlikely since the methylation is very prominent in
each case, and such a result would require large amounts of
tumor DNA in the peripheral circulation to mask the signal
from the lymphocytes. These results suggest that altered
methylation of region 2 may represent a global attribute
that is present from early development in some individuals,
while in others the increase in methylation is speciﬁc to the
malignancy.
The frequent increased M6P/IGF2R region 2 methylation
detected in ovarian cancer prompted us to evaluate whether
this is also evident in other types of cancer. We analyzed 19
inﬁltrating ductal breast carcinoma DNA samples using
HTBM followed by MS-PCR for region 2. As shown in
Figure 3E, almost half of these tumors (numbers B12-B19)
also exhibited increased or complete methylation of this
region.
Verification of M6P/IGF2R MS-PCR results by
sequencing of cloned alleles
In order to verify the methylation status of M6P/IGF2R region
2 detected by MS-PCR, we cloned PCR amplicons generated
using primers that anneal to non-CpG containing sequence and
that ﬂank the region analyzed by MS-PCR (see Figure 2).
Clones from normal lymphocyte NL11 fell into two prominent
groups, as 7of 13 clones sequenced were mostly unmethylated
at individual CpG dinucleotides within this region and the
remaining six were mostly methylated (Figure 4A). For
samples NL3 and NL12, we were able to distinguish the
two alleles because of a single nucleotide polymorphism
(G/T; rs8191722) present within the sequenced region. The
G allele of NL3 was mostly methylated (96%), while the T
allele was less methylated (54%). For NL12, both the G and T
alleles exhibited higher methylation (95 and 79%, respect-
ively). These results indicate that there is variability in the
methylation status of this region in these peripheral blood
cells.
We also analyzed ﬁve normal ovarian surface epithelium
samples (Figure 4B, OSEs1-5) that were obtained by gentle
intra-operative scraping of the surface epithelium prior to
oophorectomy. For all OSEs samples we observed a differen-
tial methylation pattern, in that the clones for each could be
grouped into mostly methylated or mostly unmethylated
categories. We also examined the normal OSE cells that
had been expanded by several passages in tissue culture
prior to harvest and DNA puriﬁcation (OSEc, see
Figure 3A and C for MS-PCR result). In this case, there
was a more random distribution of CpG methylation in the
clones (Figure 4B). These results show that normal ovarian
surface epithelium exhibits a predominant differentially
methylated pattern for this region, while culture of normal
OSE is associated with region 2 hypermethylation.
We next analyzed a series of tumors that were determined
to exhibit different types of methylation patterns by MS-PCR.
In Figure 3B, tumor 3 was scored as differentially methylated
by MS-PCR, and the sequence of the cloned alleles in
Figure 4C supports this ﬁnding. By MS-PCR, tumor 39
appeared more methylated and 52 and 43 as predominantly
methylated, and this is again in agreement with the sequencing
results.
M6P/IGF2R region 2 is hypermethylated
in ovarian cancer
In order to distinguish between the possibilities that this region
is truly hypermethylated versus the alternative explanation
that the observed methylation proﬁle is due to loss of hetero-
zygosity, we genotyped samples for the SNP mentioned
above, and in the process identiﬁed an additional SNP for
several samples located three bp upstream from rs8191722
(a CpG-altering C/T polymorphism; rs677882). We sequenced
individual clones from seven tumors that were scored as
hypermethylated or fully methylated by MS-PCR (Figure 3B
and C) and that were informative for one of these SNPs. We
determined that, in each case, both alleles were indeed present
and they both exhibited methylation. In some instances, the
pattern of methylation was suggestive of parental origin. For
example, the T allele in tumor 55, and the G alleles in tumors
47 and 59 were likely derived from the paternally inherited
chromosome, since they exhibit unmethylated CpGs in a
higher proportion than the opposite allele. Importantly, these
results indicate either that LOH is not present in these tumors,
or if it is present, paternal allele hypermethylation at region
2o fM6P/IGF2R occurred prior to LOH.
M6P/IGF2R loss of heterozygosity in ovarian cancer
In order to determine whether LOH was indeed present in
ovarian malignancies, we analyzed a polymorphism at
mRNA position 2286 in exon 16 of M6P/IGF2R (5) in four
heterozygotes using laser capture microdissected (LCM) nor-
mal and malignant cell populations (Figure 5). We considered
560 Nucleic Acids Research, 2006, Vol. 34, No. 2an allelic distribution ratio that exceeds 4:1 (>80% loss) to
be indicative of LOH; three of the four cancers analyzed met
this criterion. The remaining specimen exibited a 3.9:1 allelic
distribution, marginal for LOH. In each case, the MS-PCR
results (Figure 3B and C) also showed an increased methyla-
tion proﬁle (9,11,40), or complete methylation (43), support-
ing our conclusion that MS-PCR of region 2 is a useful method
to screen for potential LOH.
DISCUSSION
Alterations in DNA methylation are among the most common
molecular alterations in human malignancies. Detection of
aberrant methylation associated with cancer-related genes
is a promising approach to augment cancer diagnosis and
improve treatment options. Bisulﬁte modiﬁcation is prerequis-
ite for most modern techniques aimed at detecting changes
Figure 4. Analysis of M6P/IGF2R region 2 methylation status by cloning and sequencing individual alleles from HTBM-treated DNA. Each row of squares
corresponds to one individual clone; columns represent each cytosine in CpG context within the sequenced region. Filled box, methylated; unfilled, unmethylated.
(A) Normal peripheral blood lymphocytes (NL) from women without evident malignancy. NL3 and NL12 were heterozygous for a T/G SNP within the sequenced
regionallowingtheindividualparentalallelestobeidentified.(B)Sequencedclonesfromnormalovariansurfaceepithelium(OSE).OSEsdenotessamplesthatwere
obtained by gently scraping the surface epithelium from the ovary during surgical oophorectomy; OSEc are normal OSE cells that underwent several passages
in tissue culture prior to DNA extraction and analysis. (C) Methylation status of alleles cloned from ovarian malignancies that exhibited differential methylation
(3)and hypermethylation(39, 52,43) by MS-PCR. (D) Methylationstatusofclonedallelesfrom ovarianmalignanciesheterozygous foroneof two polymorphisms
(a T/G or a C/T SNP) present within the sequenced region, allowing for discrimination between parental alleles; all of these specimens exhibited hypermethylation
by MS-PCR.
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In this study, we developed and veriﬁed a high-throughput
method for bisulﬁte modiﬁcation and have used it to analyze
aberrant methylation associated with the M6P/IGF2R in
epithelial ovarian and breast cancer.
HTBM offers several practical advantages over SSBM.
First, the 96-well plate format simpliﬁes sample handling
and minimizes potential loss. HTBM eliminates the DNA
precipitation step required in the SSBM protocol, insuring
good recovery, and the need to resuspend the DNA pellet,
avoiding unnecessary shearing. No mineral oil overlay is
required, and complete treatment takes about 6 h. Because
of decreased handling, it is possible to perform parallel reac-
tions in multiple plates. This format also opens the possibility
of utilizing automation.
Wefoundthataslittle as3ngofinputgenomicDNA inboth
methods allowed for recovery of amplicons by MS-PCR and
for bisulﬁte sequencing. The apparent high degree of sensit-
ivity may be a result of the use of commercially available, high
quality genomic DNA for these experiments. In this regard,
however, we also successfully used HTBM for MS-PCR and
bisulﬁtesequencingutilizingminimalDNA fromscraped OSE
(Figure4B)andLCM samples(datanotshown).We notedthat
optimal detection of products from these specimens occurred
within the ﬁrst several weeks post-HTBM with storage at
 20 C. When 300 ng or more genomic DNA was treated
using HTBM, we were able to obtain PCR amplicons for
up to 6 months.
M6P/IGF2R is not imprinted in brain, kidney, heart, liver,
lung or placenta (10). Imprinting in other human tissues
has not been systematically investigated, but recent studies
indicate a maternal effect in the transmission of type 1
diabetes (16), suggestive of the potential for tissue-speciﬁc
imprinting. It is curious that in each case of distorted methy-
lation, hypermethylation was always observed rather than
hypomethylation. Biased loss of the paternal allele might
indicate that the gene is imprinted in these tissues. However,
if M6P/IGF2R is imprinted in humans as it is in mice, the
maternal allele is expected to be active. As such, it is unclear
why the silent allele of this putative tumor suppressor gene
would be lost, unless the driving force is another imprinted
locus in proximity to M6P/IGF2R. The most parsimonious
explanation for our ﬁndings is that region 2 is vulnerable to
acquisition of hypermethylation. This could result from a
cellular milieu that directs aberrant methylation to target
regions, and the differentially methylated status of region 2
may create a methylation ‘sink’ for the paternal allele. This
effect, if correct, is limited to this CpG island since the pro-
moter CpG island was very infrequently found to exhibit
methylation. Alternatively, hypermethylation may inﬂuence
a previously unappreciated function for region 2 in the tran-
scription of M6P/IGF2R. Our microarray data (12) support the
former hypothesis, in that there is no statistical correlation
between M6P/IGF2R expression and hypermethylation at
region 2 (data not shown). It is presently unclear whether
there is a functional link between hypermethylation of
region 2 and LOH.
M6P/IGF2R region 2 methylation status in ovarian and
breast tumors may be useful as a biomarker of disease. We
demonstrated not only that region 2 hypermethylation is an
indicator of potential LOH, but also that region 2 was very
frequently methylated on both parental alleles. The ﬁnding
that LOH was present in three of four serous epithelial ovarian
cancers exhibiting region 2 hypermethylation indicates that
the analysis of this region should prove useful for the study
of other cancers in which LOH is prominent. The other aspect
of this study, the preparation of genomic DNA using HTBM
for methylation analysis, will prove beneﬁcial for any epigen-
etic study focused on analysis of DNA methylation in a large
number of specimens.
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